Democratic leaders of the House Energy and Commerce Committee today released findings from their investigation of 14 companies that sell or help consumers sign up for short-term, limited duration health plans.

Among other findings, they said all eight plans they investigated deny claims for pre-existing conditions; that most of them “systematically exclude coverage for most major medical conditions resulting from pre-existing conditions”; and that the average broker commission for the plans they investigated was 23% compared with 2% for Affordable Care Act-compliant plans in 2018.

They also said that less than half of the premium dollars collected from consumers are spent on medical care, unlike ACA-compliant individual market plans, which are required to spend at least 80% of premium dollars on health care; and that enrollment in the plans rose 27% in 2019 to about 3 million consumers.

In addition, they said consumers who purchase this type of health plan are more likely to have substantial out-of-pocket medical costs due to the lack of coverage provided by these companies.

Related News Articles

Headline
Aetna’s new “level of severity inpatient payment” policy is now set to take effect Jan. 1, 2026, the company recently announced, along with providing…
Headline
Medicaid enrollment decreased 7.6% in fiscal year 2025 and is expected to be mostly flat in FY 2026, according to KFF’s annual Medicaid Budget Survey released…
Blog
Public
The health care field has entered a period of disruption, from sweeping coverage changes to the rise of artificial intelligence (AI)-enabled tools. The…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Perspective
Public
Staff Sgt. Ronald Shurer was awarded the Medal of Honor for his actions in Afghanistan in 2008 when he repeatedly exposed himself to enemy fire to treat…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…